newsfilter
← Latest News
Business Wire·

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst